Monopar Therapeutics (NASDAQ:MNPR) Posts Quarterly Earnings Results, Beats Estimates By $0.44 EPS

Monopar Therapeutics (NASDAQ:MNPR) announced its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.44, Zacks reports.

Monopar Therapeutics Trading Down 0.7%

NASDAQ:MNPR opened at $60.99 on Friday. The company has a market capitalization of $408.63 million, a P/E ratio of -33.51 and a beta of 1.49. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00. The business’s 50-day moving average is $56.89 and its 200 day moving average is $65.87.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds have recently made changes to their positions in MNPR. Wellington Management Group LLP purchased a new stake in shares of Monopar Therapeutics in the third quarter worth about $18,904,000. Siren L.L.C. bought a new stake in Monopar Therapeutics during the fourth quarter worth approximately $13,863,000. Deerfield Management Company L.P. bought a new stake in Monopar Therapeutics during the third quarter worth approximately $13,048,000. RA Capital Management L.P. increased its stake in Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after acquiring an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC bought a new stake in Monopar Therapeutics during the third quarter worth approximately $12,496,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MNPR has been the topic of several research analyst reports. BTIG Research restated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Chardan Capital reiterated a “buy” rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.